Vixarelimab

Phase 2Monoclonal antibody

Roche

Vixarelimab is one of 103 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Prurigo NodularisActive, not recruiting

Moderate to Severe Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 1/Phase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Prurigo NodularisPhase 2

Active, not recruiting

Moderate to Severe Ulcerative ColitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Omvoh

Eli Lilly

Phase 3

14 2

Velsipity

Pfizer

Phase 3

11 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

2 4

PTM SEMA

Gilead

Phase 3

1 5

ABX464

AAbivax S.A.

Phase 3

8 6

Ontamalimab

Takeda

Phase 3

4 7

TA-650

Tanabe Pharma Corporation

Phase 3

1 8

Budesonide MMX

Ferring

Phase 3

4 9

Simponi

Remicade

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

PreclinicalActive, not recruiting

Moderate to Severe Ulcerative Colitis

NCT06693908

Clinical

Trials by Indication[1]

Prurigo Nodularis1 trial

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Completed· Roche logo

Roche·Phase 2·NCT03816891·240 enrolled

Ulcerative Colitis1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Terminated· Roche logo

Roche·Phase 2·NCT06137183·79 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Terminated· Roche logo

Roche·Phase 2·NCT05785624·286 enrolled

Moderate to Severe Ulcerative Colitis1 trial

A Phase Ic Open-label Study to Evaluate the Pharmacodynamic Effects, Pharmacokinetics, and Safety of Vixarelimab in Patients With Moderate to Severe Active Ulcerative Colitis

Active, not recruiting· Roche logo

Roche·Preclinical·NCT06693908·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Vixarelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vixarelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vixarelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Roche

Vixarelimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Prurigo Nodularis1 trial

Ulcerative Colitis1 trial

Idiopathic Pulmonary Fibrosis1 trial

Moderate to Severe Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News